TrialPaediatric drugs2023

Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis.

Amy S Paller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.